Arimoclomol Prospective Doubleblind, Randomised, Placebo-controlled Study in Patients Diagnosed With NiemannPick Disease Type C

Trial Profile

Arimoclomol Prospective Doubleblind, Randomised, Placebo-controlled Study in Patients Diagnosed With NiemannPick Disease Type C

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 01 Dec 2017

At a glance

  • Drugs Arimoclomol (Primary)
  • Indications Niemann-Pick disease type C
  • Focus Registrational; Therapeutic Use
  • Sponsors Orphazyme
  • Most Recent Events

    • 24 Oct 2017 According to an Orphazyme media release, results of this trial expected in Q3 2018. This study, if positive, will form the basis for a single study filing for NiemannPick Disease Type C, as reported in an Orphazyme media release. The company expects to complete this trial by the end of 2020.
    • 07 Jul 2017 Planned End Date changed from 1 Dec 2017 to 1 Jun 2020.
    • 07 Jul 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Jun 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top